VER Share PerformanceMore
|52 week high||51.500 25/04/16|
|52 week low||20.000 21/04/17|
|52 week change||-28.500 (-56.30%)|
|4 week volume||6,400,142 28/03/17|
Latest News« previous» nextMore
21/04/2017 - 15:20 StockMarketWire
Panmure Gordon today downgrades its investment rating on Vernalis PLC (LON:VER) to hold (from buy) and left its pri...
21/04/2017 - 15:10 StockMarketWire
Stifel today reaffirms its hold investment rating on Vernalis PLC (LON:VER) and cut its price target to 24p (from 29p).
21/04/2017 - 11:57 StockMarketWire
Weakness in pharmaceutical stocks AstraZeneca (AZN) and Hikma (HIK), as well as consumer goods giants Reckitt Benck...
21/04/2017 - 08:46 StockMarketWire
London shares are making minor gains in early deals with multi-commodity miners benefiting from rises in industrial m...
21/04/2017 - 07:22 StockMarketWire
Vernalis said a complete response letter (CRL) from the US FDA did not raise any concerns with the formulation or pharm...
21/04/2017 - 07:01 RNS
RNS Number: 9220C Vernalis PLC 21 April 2017 21 April 2017 LSE: VER Vernalis plc receives a $2 million milestone payment from one of its drug discovery collaborations Vernalis plc announced today that it has received a $2m milestone under one of its existing research collaborations to discover novel small molecules against an undisclosed target utilising Vernali...
21/04/2017 - 07:00 RNS
RNS Number: 9275C Vernalis PLC 21 April 2017 21 April 2017 LSE: VER FDA Issues a Complete Response Letter on CCP-07 NDA Vernalis plc announces today that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for CCP-07. A CRL is issued by the FDA when it has completed it...
04/04/2017 - 12:40 StockMarketWire
Stifel today reaffirms its hold investment rating on Vernalis PLC (LON:VER) and cut its price target to 29p (from 31p).
|Dividend yield||0 %|
Equity Research (VER)
Investment into addressing barriers to higher Tuzistra XR prescribing is starting to translate into higher prescription (Rx) rates. Mid-way through the second season post launch, both Rx and sales...
FDA acceptance of the CCP-08 NDA (setting a 4 August 2017 PDUFA date) advances Vernalis towards its goal of building a speciality US franchise of extended release (ER) prescription-only (Rx) cough...
Vernalis marked its transition into a commercial-stage speciality pharma company with the September 2015 US launch of Tuzistra XR, the first product from its extended release (ER) prescription only (...
- 1 of 4
Latest discussion posts More
“Just me and him then, anyone else? M”▼
“Wow these guys really believe this is a winner. Glad I bought in last week. M”▼
“Read Edison's note on VERNALIS, out this morning, by visiting https://www.research-tree.com/company/GB00B3Y5L754 "Vernalis intends to raise #40m (gross) through the issue of ...”▼
Codes & Symbols
|Symbols||VER, LSE:VER, VER.L, VER:LN, LON:VER, XLON:VER|